APOL Stock Overview
Apollon Formularies PLC operates as a medical cannabis pharmaceutical company.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Apollon Formularies PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.00095 |
| 52 Week High | UK£0 |
| 52 Week Low | UK£0 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | -36.67% |
| 1 Year Change | -45.71% |
| 3 Year Change | -98.00% |
| 5 Year Change | n/a |
| Change since IPO | -98.69% |
Recent News & Updates
Recent updates
Shareholder Returns
| APOL | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 0% | -1.3% | -0.9% |
| 1Y | -45.7% | -5.5% | -1.8% |
Return vs Industry: APOL underperformed the UK Pharmaceuticals industry which returned -5.5% over the past year.
Return vs Market: APOL underperformed the UK Market which returned -1.8% over the past year.
Price Volatility
| APOL volatility | |
|---|---|
| APOL Average Weekly Movement | 6.8% |
| Pharmaceuticals Industry Average Movement | 8.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: APOL's share price has been volatile over the past 3 months.
Volatility Over Time: APOL's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | n/a | Stephen Barnhill | www.apollon.org.uk |
Apollon Formularies PLC operates as a medical cannabis pharmaceutical company. It offers hybrid medical cannabis pharmaceutical strains, technology, formulations, and treatment products, such as cannabis oil vape, oral tincture, and perscribed capsules under the Apollon NAUSEA, Apollon PAIN, Apollon SLEEP, Apollon ANTI-INFLAMMATORY, Apollon SEIZURES, Apollon APPETITE, and Apollon CANCER names. Apollon Formularies PLC was founded in 2014 and is based in Douglas, the United Kingdom.
Apollon Formularies PLC Fundamentals Summary
| APOL fundamental statistics | |
|---|---|
| Market cap | UK£732.63k |
| Earnings (TTM) | -UK£1.05m |
| Revenue (TTM) | UK£362.72k |
0.0x
P/S Ratio0.0x
P/E RatioIs APOL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| APOL income statement (TTM) | |
|---|---|
| Revenue | UK£362.72k |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£362.72k |
| Other Expenses | UK£1.41m |
| Earnings | -UK£1.05m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did APOL perform over the long term?
See historical performance and comparison